Sodium thiosulfate injection (single-agent) Review

What is sodium thiosulfate used for?

Regulatory/prescribing sources list sodium thiosulfate injection for sequential use with sodium nitrite in the treatment of acute cyanide poisoning. Clinical summaries also document its use to lessen some side effects of cisplatin chemotherapy; RxList provides protocols for both nephroprotection and local extravasation treatment. The literature and practice reviews also report off-label applications such as treatment of calciphylaxis in selected patients.

Examples of cited dosing regimens from the sources: cyanide poisoning—adult 12.5 g IV infused over 10–20 minutes (pediatric 7 g/m², maximum 12.5 g); cisplatin nephrotoxicity protocol—4 g/m² IV bolus followed by 12 g/m² IV infusion over 6 hours; extravasation—use of a 1/6 molar solution with specified local injection technique.

How is sodium thiosulfate dosed and prepared?

Published dosing varies by indication. For cyanide poisoning, the commonly cited adult dose is 12.5 g IV infused over 10–20 minutes; pediatric dosing is weight/area‑based at 7 g/m² up to 12.5 g. For cisplatin nephroprotection RxList lists a regimen of 4 g/m² IV bolus then 12 g/m² over 6 hours. For cisplatin extravasation a 1/6 molar solution is described (examples: prepare by mixing 4 mL of 10% solution with 6 mL sterile water, or 1.6 mL of 25% solution with 8.4 mL sterile water) with local injections around the affected site.

Administration requires intravenous access and careful preparation; some indications call for bolus plus prolonged infusion. The product labeling and clinical guidance recommend monitoring for metabolic/electrolyte effects and, in some contexts, for thiocyanate accumulation.

Side effects, monitoring and known risks

Reported adverse effects include volume overload, metabolic acidosis, gastrointestinal symptoms (nausea and vomiting), and electrolyte changes such as hypernatremia and low blood potassium. Additional noted findings include decreased hemoglobin and the need to monitor for thiocyanate toxicity in relevant clinical contexts.

Because sodium thiosulfate can contribute to metabolic and fluid-electrolyte derangements, clinicians should monitor vital signs, fluid status, basic metabolic panel (sodium, potassium, bicarbonate), and hemoglobin. The safety profile is the principal limitation when using the drug for prolonged infusions or in patients with limited cardiorespiratory reserve.

How well does it work for its main indications?

For acute cyanide poisoning, sodium thiosulfate is part of an accepted antidotal regimen (sequential use with sodium nitrite) per prescribing information; standard adult dosing (12.5 g IV) is provided in the package guidance. For mitigation of cisplatin toxicity, clinical sources (Mayo Clinic, RxList) describe its use to lessen side effects and specific infusion regimens for nephroprotection.

Evidence summaries and off-label literature (e.g., calciphylaxis reviews) report clinical use and case-series data for non‑FDA‑approved indications, but the strongest, directive dosing recommendations exist for cyanide poisoning and defined cisplatin-protection regimens.

Preparation, compatibility and clinical considerations

The injection requires appropriate dilution or specific solution preparation for extravasation treatment (1/6 molar solution examples are given in RxList). Clinicians should follow institutional protocols when preparing bolus-plus-infusion regimens (e.g., 4 g/m² bolus then 12 g/m² over 6 hours for cisplatin nephroprotection).

Practical limitations include IV access and infusion time, the need to monitor electrolytes and fluid status during and after administration, and recognition that some clinical uses (for example calciphylaxis) are off-label and guided largely by case reports and practice reviews rather than large randomized trials.

Pros & Cons

• ✅ Indicated antidote for acute cyanide poisoning with adult dosing specified as 12.5 g IV infused over 10–20 minutes (per prescribing information).
• ✅ Documented regimen for cisplatin nephroprotection: 4 g/m² IV bolus followed by 12 g/m² IV infusion over 6 hours (RxList).
• ✅ Prepared formulations and explicit extravasation instructions available (1/6 molar solution preparation: e.g., 4 mL of 10% solution + 6 mL sterile water) for local treatment of cisplatin extravasation.
• ✅ Used off-label in serious conditions like calciphylaxis, where clinical reviews describe its application when other measures are insufficient (PMC/NIH).

• ❌ Adverse effect profile includes volume overload and metabolic acidosis; significant monitoring (fluids, electrolytes, hemoglobin) is required.
• ❌ Electrolyte disturbances reported: hypernatremia and low blood potassium (hypokalemia) and potential decreased hemoglobin (MedicineNet, ScienceDirect, RxList).
• ❌ Some uses, such as calciphylaxis treatment, are off-label and not FDA‑approved; clinicians must rely on case series and reviews rather than large randomized trials (PMC/Off‑Label Drug Facts).
• ❌ Risk of thiocyanate-related toxicity in certain scenarios—guidance recommends monitoring where relevant (RxList).

How It Compares to the Competition

• Sodium nitrite — Used sequentially with sodium thiosulfate as part of standard antidotal therapy for cyanide poisoning; typically given before thiosulfate in package protocols.
• Hydroxocobalamin (Cyanokit) — An alternative cyanide antidote used in clinical practice; differs in mechanism and administration from thiosulfate-based regimens.
• Amifostine — An alternative radioprotective/chemoprotective agent used to reduce some cisplatin-related toxicities in specific oncology protocols.

Who Should Buy This & Who Should Skip It

Buy it if: Hospital pharmacists, emergency physicians, medical toxicologists, oncologists and nephrologists who manage acute cyanide exposures, cisplatin chemotherapy regimens, or specific off‑label indications (e.g., calciphylaxis) should have IV sodium thiosulfate available and know the institution's dosing protocols.

Skip it if: Outpatient clinicians or non-clinical users who cannot provide IV administration and monitoring should not use this product; patients with limited cardiorespiratory reserve or uncontrolled electrolyte or volume disorders may be better served by alternative interventions or specialist-led care.